In summer 2023, ORNL's Prasanna Balaprakash was invited to speak at a roundtable discussion focused on the importance of academic artificial intelligence research and development hosted by the White House Office of Science and Technology Policy and the U.S. National Science Foundation.
The 21st Symposium on Separation Science and Technology for Energy Applications, Oct. 23-26 at the Embassy Suites by Hilton West in Knoxville, attracted 109 researchers, including some from Austria and the Czech Republic. Besides attending many technical sessions, they had the opportunity to tour the Graphite Reactor, High Flux Isotope Reactor and both supercomputers at ORNL.
Marcel Demarteau is director of the Physics Division at the Department of Energy’s Oak Ridge National Laboratory. For topics from nuclear structure to astrophysics, he shapes ORNL’s physics research agenda.
Porter Bailey started and will end his 33-year career at ORNL in the same building: 7920 of the Radiochemical Engineering Development Center.
East Tennessee occupies a special place in nuclear history. In 1943, the world’s first continuously operating reactor began operating on land that would become ORNL.
The University of Texas at San Antonio (UTSA) has formally launched the Cybersecurity Manufacturing Innovation Institute (CyManII), a $111 million public-private partnership.
A multi-institutional team, led by a group of investigators at Oak Ridge National Laboratory, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease. The feat has earned the team a finalist nomination for the Association of Computing Machinery, or ACM, Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
ORNL and three partnering institutions have received $4.2 million over three years to apply artificial intelligence to the advancement of complex systems in which human decision making could be enhanced via technology.
NellOne Therapeutics has licensed a drug delivery system from the Department of Energy’s Oak Ridge National Laboratory that is designed to transport therapeutics directly to cells infected by SARS-CoV-2, the virus causing COVID-19.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.